KLF10 (Krüppel-like factor 10), also known as TIEG1 (TGF-β-inducible early gene 1), is a transcription factor belonging to the Krüppel-like family of zinc finger proteins. It plays a critical role in regulating cellular processes such as proliferation, differentiation, apoptosis, and extracellular matrix remodeling, primarily by mediating TGF-β (transforming growth factor-beta) signaling pathways. KLF10 is implicated in various physiological and pathological conditions, including cancer progression, fibrosis, metabolic disorders, and cardiovascular diseases.
Antibodies targeting KLF10 are essential tools for studying its expression, localization, and function in biological systems. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP) to detect KLF10 protein levels or investigate its interaction with DNA and other molecular partners. Researchers frequently employ KLF10 antibodies to explore its involvement in TGF-β-mediated responses, tumor suppression, osteoblast differentiation, and metabolic syndrome-related pathways.
Quality validation of KLF10 antibodies is crucial, often involving knockout (KO) cell lines or tissues to confirm specificity. Commercial KLF10 antibodies are available from multiple suppliers, with variations in host species (e.g., rabbit, mouse), clonality (monoclonal/polyclonal), and conjugation tags. Proper experimental controls are necessary to ensure accurate interpretation of results, given potential cross-reactivity with related KLF family members.